Bausch Health Companies Investor Conference Presentation Deck
Bausch Pharma¹ At-A-Glance
Key Leadership Appointments
Tom Appio
Chief Executive Officer
Tom Vadaketh
Chief Financial Officer
Seana Carson
General Counsel
Bob Spurr
President, U.S. Business
Bausch Pharma Revenue Portfolio 2,3
(Excluding Global Solta Revenue)
Generics
4%
Neuro
and Other
14%
Ortho Dermatologics
6%
Xifaxan
rifaximin 550 mg tablets
Dentistry
2%
Salix
47%
International Rx
27%
Trulance™
(plecanatide)
RELISTOR
methylnaltrexone bromide
Post Separation Profile
Expected Tax Rate: -10-12%
Domiciled: Canada; U.S.
corporate offices will
continue to be in Bridgewater,
NJ
Remain listed on: NYSE and
TSX
Wellbutrin XL
bupropion HCI 150 mg, 300 mg
EXTENDED-RELEASE TABLETS
Bedoyecta
Aplenzin.com
bupropion HBr 622m
extended-release tablets
JUBLIA
(efinaconazole)
Topical Solution 10%
1. The remainder of Bausch Health is referred to as "Bausch Pharma" and will assume a new name upon separation from the Company's eye health business, Bausch + Lomb.
BAUSCH-Health 2. Bausch a are determined subtracting Bausch + Lomb revenues for the applicable from total Health revenues
period. See slide 2 and the Appendix for further non-GAAP information. For the purposes of this slide, Bausch Pharma Revenue has been further adjusted to subtract Global Solta revenue for the
applicable period.
3. YTD Revenue as of 9/30/21.View entire presentation